Monte Rosa Therapeutics, Inc. Common Stock GLUE
Analyst Ratings
- Consensus
- Buy — 5 Buy · 0 Hold · 0 Sell (5 analysts)
- Avg. Price Target
- $29.20 (+111.0% upside)
Key Stats
- Today's Range
- $13.79 – $14.31
- 50-Day Range
- $13.12 – $25.22
- 52-Week Range
- $4.12 – $25.77
- Volume
- 805K shs
- Average Volume
- 1.38 million shs
- Market Cap
- $1.18 billion
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 2.42
- Price / Sales
- —
Short Interest
- Short Interest
- 0.86%
- Days to Cover
- 1.36
About Monte Rosa Therapeutics, Inc. Common Stock
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).
Related Stocks
Compare head-to-head: GLUE vs AMGN·GLUE vs MRNA·GLUE vs HALO·GLUE vs KRYS
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.